{
  "abstract": "Introduction The rising prevalence of inflammatory bowel disease (IBD) and the rapid expansion of new medical therapies have put unprecedented demand on IBD services. To support safe, timely care, we established a specialist pharmacist-led clinic for patients commencing Janus kinase inhibitors (JAKi; upadacitinib or filgotinib), where a Specialist Pharmacist counselled, initiated and monitored, and guided transition to maintenance therapy.Methods We conducted a retrospective analysis of clinical records of patients with IBD commenced on a JAKi at the Royal Free London NHS Foundation Trust, a tertiary referral IBD centre, between January 2023 and November 2025, comparing outcomes before and after implementation of the pharmacist-led JAKi clinic in November 2024.Results 67 patients were commenced on a JAKi within this time, 25 (37.3%) were female. Mean age at initiation was 37.2 (SD 11.9). 37 (55.2%) patients had Crohn’s disease and 30 (44.8%) had ulcerative colitis. 48 (71.6%) were commenced on upadacitinib and 19 (28.4%) on filgotinib. 32 (47.8%) patients were initiated on treatment prior to, and 35 (52.2%) after, Introduction of the pharmacist-led JAKi clinic.The pharmacist-led JAKi clinic reduced the mean time from the decision to start treatment to the commencement from 70.2 to 25.1 days. Miscommunication/misunderstanding causing treatment delays or gaps occurred in 18.8% (6/32) of patients prior to the clinic, but none after its introduction. Documentation of pre-initiation counselling improved from 84.4% (27/32) to 100% (35/35), including counselling on VTE, infections, shingles, acne, and cholesterol. Documented counselling regarding pregnancy prevention in patients with childbearing potential rose from 16.7% (2/12) to 100% (12/12). Adherence to monthly blood monitoring during induction increased from 46.9% (15/32) to 72.4% (21/29), and patients receiving post-induction reviews prior to transitioning to maintenance therapy improved from 56.3% (18/32) to 100% (13/13).Conclusions Our specialist pharmacist-led JAKi clinic reduced the time to treatment initiation, eliminated communication-related delays, improved pre-initiation counselling, adherence to blood monitoring, and facilitated timely post-induction reviews. These findings demonstrate the value of pharmacist-led clinics in optimising patient care and improving patient safety within a busy tertiary IBD service.",
  "authors": [
    {
      "affiliations": [
        "Royal Free London NHS Foundation Trust, London, United Kingdom"
      ],
      "name": "Aqib Chowdhury"
    },
    {
      "affiliations": [
        "Royal Free London NHS Foundation Trust, London, United Kingdom"
      ],
      "name": "Nina Taherzadeh"
    },
    {
      "affiliations": [
        "Royal Free London NHS Foundation Trust, London, United Kingdom"
      ],
      "name": "Alex Cheshire"
    },
    {
      "affiliations": [
        "Royal Free London NHS Foundation Trust, London, United Kingdom"
      ],
      "name": "Gamal Erian"
    },
    {
      "affiliations": [
        "Royal Free London NHS Foundation Trust, London, United Kingdom"
      ],
      "name": "Georgia Woodfield"
    },
    {
      "affiliations": [
        "Royal Free London NHS Foundation Trust, London, United Kingdom"
      ],
      "name": "Zaeem Cader"
    },
    {
      "affiliations": [
        "Royal Free London NHS Foundation Trust, London, United Kingdom"
      ],
      "name": "James C Lee"
    },
    {
      "affiliations": [
        "Royal Free London NHS Foundation Trust, London, United Kingdom"
      ],
      "name": "Charles Murray"
    },
    {
      "affiliations": [
        "Royal Free London NHS Foundation Trust, London, United Kingdom"
      ],
      "name": "Nuala O’Shea"
    }
  ],
  "title": "FP22 Impact of implementing a pharmacist-led selective JAK1 inhibitor clinic on IBD care: a retrospective pre-post study",
  "uid": "0463b65c-9e15-515e-905b-fb9558eaa8ab"
}